# Pacific Biosciences of California, Inc.: overview

PACB · Nasdaq · CIK 1299130 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pacb.md) · [Financials](/companies/pacb/financials.md) · [Filings](/companies/pacb/filings.md) · [Insiders](/companies/pacb/insiders.md)

Latest reported revenue: [$39.0m](/filings/0001299130-26-000122.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001299130-26-000122).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [40.0](/filings/0001299130-25-000168.md) | [39.2 d](/filings/0001299130-26-000034.md) | [37.2](/filings/0001299130-26-000081.md) | [39.8](/filings/0001299130-26-000122.md) | [38.4](/filings/0001299130-25-000168.md) | [44.6 d](/filings/0001299130-26-000034.md) | [37.2](/filings/0001299130-26-000081.md) | [39.0](/filings/0001299130-26-000122.md) |
| Gross margin | % | [25.0%](/filings/0001299130-25-000168.md) | [25.6% d](/filings/0001299130-26-000034.md) | [(3.7%)](/filings/0001299130-26-000081.md) | [36.9%](/filings/0001299130-26-000122.md) | [41.4%](/filings/0001299130-25-000168.md) | [37.1% d](/filings/0001299130-26-000034.md) | [34.5%](/filings/0001299130-26-000081.md) | [32.4%](/filings/0001299130-26-000122.md) |
| Operating margin | % | [(160.3%)](/filings/0001299130-25-000168.md) | [(390.1%) d](/filings/0001299130-26-000034.md) | [(1154.5%)](/filings/0001299130-26-000081.md) | [(112.8%)](/filings/0001299130-26-000122.md) | [(101.1%)](/filings/0001299130-25-000168.md) | [(92.3%) d](/filings/0001299130-26-000034.md) | [(22.5%)](/filings/0001299130-26-000081.md) | [(114.4%)](/filings/0001299130-26-000122.md) |
| Net margin | % | [(151.9%)](/filings/0001299130-25-000168.md) | [6.0% d](/filings/0001299130-26-000034.md) | [(1146.8%)](/filings/0001299130-26-000081.md) | [(105.4%)](/filings/0001299130-26-000122.md) | [(98.9%)](/filings/0001299130-25-000168.md) | [(90.4%) d](/filings/0001299130-26-000034.md) | [(22.3%)](/filings/0001299130-26-000081.md) | [(114.7%)](/filings/0001299130-26-000122.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0001299130-25-000168.md) | not reported | [(1.44)](/filings/0001299130-26-000081.md) | [(0.14)](/filings/0001299130-26-000122.md) | [(0.13)](/filings/0001299130-25-000168.md) | not reported | [(0.03)](/filings/0001299130-26-000081.md) | [(0.14)](/filings/0001299130-26-000122.md) |
| Free cash flow | $m | [(46.3) d](/filings/0001299130-25-000168.md) | [(32.3) d](/filings/0001299130-26-000034.md) | [(45.4)](/filings/0001299130-26-000081.md) | [(29.9) d](/filings/0001299130-26-000122.md) | [(18.8) d](/filings/0001299130-25-000168.md) | [(19.9) d](/filings/0001299130-26-000034.md) | [(47.7)](/filings/0001299130-26-000081.md) | [(37.1) d](/filings/0001299130-26-000122.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [131](/filings/0001299130-24-000054.md) | [128](/filings/0001299130-25-000061.md) | [201](/filings/0001299130-26-000034.md) | [154](/filings/0001299130-26-000034.md) | [160](/filings/0001299130-26-000034.md) |
| Gross margin | % | [45.1%](/filings/0001299130-24-000054.md) | [38.2%](/filings/0001299130-25-000061.md) | [26.3%](/filings/0001299130-26-000034.md) | [24.2%](/filings/0001299130-26-000034.md) | [28.6%](/filings/0001299130-26-000034.md) |
| Operating margin | % | [(161.2%)](/filings/0001299130-24-000054.md) | [(239.4%)](/filings/0001299130-25-000061.md) | [(166.8%)](/filings/0001299130-26-000034.md) | [(308.0%)](/filings/0001299130-26-000034.md) | [(346.2%)](/filings/0001299130-26-000034.md) |
| Net margin | % | [(138.9%)](/filings/0001299130-24-000054.md) | [(244.9%)](/filings/0001299130-25-000061.md) | [(153.0%)](/filings/0001299130-26-000034.md) | [(201.2%)](/filings/0001299130-26-000034.md) | [(341.5%)](/filings/0001299130-26-000034.md) |
| Diluted EPS | $ per share | [(0.89)](/filings/0001299130-24-000054.md) | [(1.40)](/filings/0001299130-25-000061.md) | [(1.21)](/filings/0001299130-26-000034.md) | [(1.59)](/filings/0001299130-26-000034.md) | [(1.82)](/filings/0001299130-26-000034.md) |
| Free cash flow | $m | [(117)](/filings/0001299130-24-000054.md) | [(280)](/filings/0001299130-25-000061.md) | [(268)](/filings/0001299130-26-000034.md) | [(212)](/filings/0001299130-26-000034.md) | [(114)](/filings/0001299130-26-000034.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pacb/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $54.3m | 32,339,550 |  | Added +7,072,121 |
| [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $50.0m | 29,781,416 |  | Reduced −6,491,872 |
| [SOFTBANK GROUP CORP.](/funds/1065521.md) | 2026-06-30 | $34.4m | 20,451,570 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $22.5m | 13,397,934 |  | Added +620,485 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $12.8m | 7,606,518 |  | Added +631,252 |
| [Sumitomo Mitsui Trust Group, Inc.](/funds/1475365.md) | 2026-06-30 | $10.1m | 6,009,715 |  | Reduced −1,028,272 |
| [Amova Asset Management Americas, Inc.](/funds/1480751.md) | 2026-06-30 | $10.0m | 6,009,715 |  | Reduced −1,028,272 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $10.0m | 5,961,175 |  | Reduced −160,541 |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $8.0m | 4,787,300 |  | Added +4,501,600 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $7.1m | 4,242,599 |  | Added +732,986 |

## Recent filings

[All 959 filings](/companies/pacb/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 21:30 ET | [10-Q](/filings/0001299130-26-000122.md) | Quarterly report, period 2026-06-30 | 0001299130-26-000122 |
| 2026-08-05 | 20:23 ET | [8-K](/filings/0001299130-26-000117.md) | 2.02 Results of operations; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001299130-26-000117 |
| 2026-07-09 | 20:32 ET | [8-K](/filings/0001299130-26-000111.md) | 5.02 Departure or appointment of officers or directors | 0001299130-26-000111 |
| 2026-06-04 | 21:19 ET | [8-K](/filings/0001299130-26-000092.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001299130-26-000092 |
| 2026-05-08 | 21:27 ET | [10-Q](/filings/0001299130-26-000081.md) | Quarterly report, period 2026-03-31 | 0001299130-26-000081 |
| 2026-05-07 | 20:14 ET | [8-K](/filings/0001299130-26-000076.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001299130-26-000076 |
| 2026-04-23 | 20:40 ET | [DEF 14A](/filings/0001299130-26-000064.md) | Proxy statement, period 2026-06-03 | 0001299130-26-000064 |
| 2026-03-06 | 21:06 ET | [8-K](/filings/0001299130-26-000053.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001299130-26-000053 |
| 2026-03-05 | 13:34 ET | [8-K](/filings/0001299130-26-000046.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001299130-26-000046 |
| 2026-02-25 | 21:03 ET | [10-K](/filings/0001299130-26-000034.md) | Annual report, period 2025-12-31 | 0001299130-26-000034 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001299130-26-000034.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c110388c-c024-478f-89b4-cc76a219a34d)

## About the filer

- CIK: 1299130
- Tickers: PACB
- Exchange: Nasdaq
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.